HCQ and Leronlimab are two totally different drugs. HCQ can be useful but it has to be used early so the window of opportunity is smaller than Leronlimab which can treat even patients in severe/critical stage. IMHO there is no conflict between HCQ and Leronlimab. However, HCQ and Rem is a different story. Since Rem selling point is the 4 days improvement but not the mortality rate, there is too much business opportunity overlap between HCQ and Rem. Hence, HCQ must die.